Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 7/20 | 0.40 |
| ▸ | PPARA | Q07869 | 3/20 | 0.40 |
| ▸ | PPARG | P37231 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.35 |
| ▸ | IDH1 | O75874 | 2/20 | 0.34 |
| ▸ | FRK | P42685 | 1/20 | 0.34 |
| ▸ | CAMK2B | Q13554 | 1/20 | 0.34 |
| ▸ | CAMK2G | Q13555 | 1/20 | 0.34 |
| ▸ | CAMK2D | Q13557 | 1/20 | 0.34 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.33 |
| ▸ | GCGR | P47871 | 1/20 | 0.33 |
| ▸ | GIPR | P48546 | 1/20 | 0.33 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.33 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.33 |
| ▸ | CCR1 | P32246 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.32 |
| ▸ | CRHBP | P24387 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4327180 | 0.90 | PPARD (0.47) | PPARDPPARAPPARGFFAR1GCGR | |
| SCHEMBL4097006 | 0.85 | HSD17B1 (0.35) | PPARDPPARAPPARGMAPTFRK | |
| SCHEMBL4324880 | 0.83 | PPARD (0.50) | PPARDPPARAPPARGMAPTFFAR1 | |
| SCHEMBL30003690 | 0.82 | PPARD (0.40) | PPARDPPARAPPARG | |
| SCHEMBL24656247 | 0.82 | PPARD (0.40) | PPARDPPARAPPARG | |
| SCHEMBL1765904 | 0.81 | PPARD (0.51) | PPARDPPARAPPARG | |
| SCHEMBL1765881 | 0.80 | PPARA (0.47) | PPARDPPARAPPARG | |
| SCHEMBL30003517 | 0.80 | PPARD (0.37) | PPARDPPARAPPARGMAPT | |
| SCHEMBL24656252 | 0.80 | PPARD (0.37) | PPARDPPARAPPARGMAPT | |
| SCHEMBL1031012 | 0.79 | PPARD (0.35) | PPARDPPARAPPARGMAPTIDH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2014652-B1 | ACTIVATING AGENT FOR PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR | NIPPON CHEMIPHAR CO (JP) | 2014-08-06 | — | — | EP | disclosed |
| US-20130217734-A1 | ACTIVATING AGENT FOR PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA | NIPPON CHEMIPHAR CO., LTD. (JP) | 2013-08-22 | — | — | US | disclosed |
| US-8404726-B2 | Activating agent for peroxisome proliferator activated receptor δ | NIPPON CHEMIPHAR CO. LTD. (JP) | 2013-03-26 | — | — | US | disclosed |
| US-20090298896-A1 | ACTIVATING AGENT FOR PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA | NIPPON CHEMIPHAR CO. LTD | 2009-12-03 | — | — | US | disclosed |
| EP-2014652-A1 | ACTIVATING AGENT FOR PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR | Nippon Chemiphar Co., Ltd. (JP) | 2009-01-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298896-A1 | ACTIVATING AGENT FOR PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA | PPARA, PPARG, PPARD | PPARD 3/4885PPARA 1/4885PPARG 2/4885 |
| US-20130217734-A1 | ACTIVATING AGENT FOR PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA | PPARA, PPARG, PPARD | PPARD 3/4885PPARA 1/4885PPARG 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.